001021437 001__ 1021437
001021437 005__ 20260223122456.0
001021437 0247_ $$2doi$$a10.3389/fphar.2023.1120360
001021437 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-00733
001021437 0247_ $$2pmid$$a37007008
001021437 0247_ $$2WOS$$aWOS:000960653700001
001021437 037__ $$aFZJ-2024-00733
001021437 082__ $$a610
001021437 1001_ $$0P:(DE-HGF)0$$aGrohs, Laura$$b0
001021437 245__ $$aDiclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor
001021437 260__ $$aLausanne$$bFrontiers Media$$c2023
001021437 3367_ $$2BibTeX$$aMISC
001021437 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
001021437 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1769165179_19119
001021437 3367_ $$026$$2EndNote$$aChart or Table
001021437 3367_ $$2DataCite$$aDataset
001021437 3367_ $$2ORCID$$aDATA_SET
001021437 3367_ $$2DINI$$aResearchData
001021437 500__ $$aThis study was funded by grants from DeutscheForschungsgemeinschaft (DFG), Germany (grant numbers HA6095/1-1 and HA 6095/1-2) to RH and to J-PM (grant numberMA 7525/2-1, as part of the Research Unit FOR 5046, project P2)and by a grant from the Interdisciplinary Centre for ClinicalResearch within the Faculty of Medicine at the RWTH AachenUniversity (IZKF TN1-1/IA 532001 and TN1-5/IA 532005).
001021437 520__ $$aIntroduction: The P2X3 receptor (P2X3R), an ATP-gated non-selective cation channel of the P2X receptor family, is expressed in sensory neurons and involved in nociception. P2X3R inhibition was shown to reduce chronic and neuropathic pain. In a previous screening of 2000 approved drugs, natural products, and bioactive substances, various non-steroidal anti-inflammatory drugs (NSAIDs) were found to inhibit P2X3R-mediated currents. Methods: To investigate whether the inhibition of P2X receptors contributes to the analgesic effect of NSAIDs, we characterized the potency and selectivity of various NSAIDs at P2X3R and other P2XR subtypes using two-electrode voltage clamp electrophysiology. Results: We identified diclofenac as a hP2X3R and hP2X2/3R antagonist with micromolar potency (with IC50 values of 138.2 and 76.7 µM, respectively). A weaker inhibition of hP2X1R, hP2X4R, and hP2X7R by diclofenac was determined. Flufenamic acid (FFA) inhibited hP2X3R, rP2X3R, and hP2X7R (IC50 values of 221 µM, 264.1 µM, and ∼900 µM, respectively), calling into question its use as a non-selective ion channel blocker, when P2XR-mediated currents are under study. Inhibition of hP2X3R or hP2X2/3R by diclofenac could be overcome by prolonged ATP application or increasing concentrations of the agonist α,β-meATP, respectively, indicating competition of diclofenac and the agonists. Molecular dynamics simulation showed that diclofenac largely overlaps with ATP bound to the open state of the hP2X3R. Our results suggest a competitive antagonism through which diclofenac, by interacting with residues of the ATP-binding site, left flipper, and dorsal fin domains, inhibits the gating of P2X3R by conformational fixation of the left flipper and dorsal fin domains. In summary, we demonstrate the inhibition of the human P2X3 receptor by various NSAIDs. Diclofenac proved to be the most effective antagonist with a strong inhibition of hP2X3R and hP2X2/3R and a weaker inhibition of hP2X1R, hP2X4R, and hP2X7R. Discussion: Considering their involvement in nociception, inhibition of hP2X3R and hP2X2/3R by micromolar concentrations of diclofenac, which are rarely reached in the therapeutic range, may play a minor role in analgesia compared to the high-potency cyclooxygenase inhibition but may explain the known side effect of taste disturbances caused by diclofenac.
001021437 536__ $$0G:(DE-HGF)POF4-5243$$a5243 - Information Processing in Distributed Systems (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001021437 536__ $$0G:(GEPRIS)426950122$$aDFG project G:(GEPRIS)426950122 - FOR 5046: Integrative Analyse epithelialer SLC26 Anionentransporter – von der molekularen Struktur zur Pathophysiologie (426950122)$$c426950122$$x1
001021437 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001021437 7001_ $$0P:(DE-HGF)0$$aCheng, Linhan$$b1
001021437 7001_ $$0P:(DE-HGF)0$$aCönen, Saskia$$b2
001021437 7001_ $$0P:(DE-Juel1)189098$$aHaddad, Bassam G.$$b3$$ufzj
001021437 7001_ $$0P:(DE-HGF)0$$aBülow, Astrid$$b4
001021437 7001_ $$0P:(DE-HGF)0$$aToklucu, Idil$$b5
001021437 7001_ $$0P:(DE-HGF)0$$aErnst, Lisa$$b6
001021437 7001_ $$0P:(DE-HGF)0$$aKörner, Jannis$$b7
001021437 7001_ $$0P:(DE-HGF)0$$aSchmalzing, Günther$$b8
001021437 7001_ $$0P:(DE-HGF)0$$aLampert, Angelika$$b9
001021437 7001_ $$0P:(DE-Juel1)156429$$aMachtens, Jan-Philipp$$b10$$ufzj
001021437 7001_ $$0P:(DE-HGF)0$$aHausmann, Ralf$$b11$$eCorresponding author
001021437 773__ $$0PERI:(DE-600)2587355-6$$a10.3389/fphar.2023.1120360$$gVol. 14, p. 1120360$$p1120360$$tFrontiers in pharmacology$$v14$$x1663-9812$$y2023
001021437 8564_ $$uhttps://juser.fz-juelich.de/record/1021437/files/Frontiers_Pharmacology_Machtens_Haddad_Hausmann_03_2023.pdf$$yOpenAccess
001021437 8564_ $$uhttps://juser.fz-juelich.de/record/1021437/files/Frontiers_Pharmacology_Machtens_Haddad_Hausmann_03_2023.gif?subformat=icon$$xicon$$yOpenAccess
001021437 8564_ $$uhttps://juser.fz-juelich.de/record/1021437/files/Frontiers_Pharmacology_Machtens_Haddad_Hausmann_03_2023.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001021437 8564_ $$uhttps://juser.fz-juelich.de/record/1021437/files/Frontiers_Pharmacology_Machtens_Haddad_Hausmann_03_2023.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001021437 8564_ $$uhttps://juser.fz-juelich.de/record/1021437/files/Frontiers_Pharmacology_Machtens_Haddad_Hausmann_03_2023.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001021437 909CO $$ooai:juser.fz-juelich.de:1021437$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001021437 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b2$$kFZJ
001021437 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)189098$$aForschungszentrum Jülich$$b3$$kFZJ
001021437 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156429$$aForschungszentrum Jülich$$b10$$kFZJ
001021437 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5243$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001021437 9141_ $$y2024
001021437 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
001021437 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001021437 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PHARMACOL : 2022$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T14:28:21Z
001021437 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T14:28:21Z
001021437 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001021437 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T14:28:21Z
001021437 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT PHARMACOL : 2022$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
001021437 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
001021437 920__ $$lyes
001021437 9201_ $$0I:(DE-Juel1)IBI-1-20200312$$kIBI-1$$lMolekular- und Zellphysiologie$$x0
001021437 980__ $$adataset
001021437 980__ $$aVDB
001021437 980__ $$aUNRESTRICTED
001021437 980__ $$ajournal
001021437 980__ $$aI:(DE-Juel1)IBI-1-20200312
001021437 9801_ $$aFullTexts